{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:53:04Z","timestamp":1792021984939,"version":"4.4.0"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,6,21]],"date-time":"2018-06-21T00:00:00Z","timestamp":1529539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s00345-018-2380-x","type":"journal-article","created":{"date-parts":[[2018,6,21]],"date-time":"2018-06-21T09:27:34Z","timestamp":1529573254000},"page":"1981-1995","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":120,"title":["An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8443-8453","authenticated-orcid":false,"given":"Francesco","family":"Soria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Droller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yair","family":"Lotan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gontero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"D\u2019Andrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kilian M.","family":"Gust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Babjuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Palou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,21]]},"reference":[{"key":"2380_CR1","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.eururo.2015.10.024","volume":"69","author":"J Leal","year":"2016","unstructured":"Leal J, Luengo-Fernandez R, Sullivan R, Witjes JA (2016) Economic burden of bladder cancer across the European union. Eur Urol 69:438\u2013447. https:\/\/doi.org\/10.1016\/j.eururo.2015.10.024","journal-title":"Eur Urol"},{"key":"2380_CR2","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s00345-009-0395-z","volume":"27","author":"KD Sievert","year":"2009","unstructured":"Sievert KD, Amend B, Nagele U, Schilling D, Bedke J, Horstmann M et al (2009) Economic aspects of bladder cancer: what are the benefits and costs? World J Urol 27:295\u2013300. https:\/\/doi.org\/10.1007\/s00345-009-0395-z","journal-title":"World J Urol"},{"key":"2380_CR3","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","volume":"71","author":"M Babjuk","year":"2016","unstructured":"Babjuk M, B\u00f6hle A, Burger M, Capoun O, Cohen D, Comp\u00e9rat EM et al (2016) EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update. Eur Urol 71:447\u2013461. https:\/\/doi.org\/10.1016\/j.eururo.2016.05.041 (n.d.)","journal-title":"Eur Urol"},{"key":"2380_CR4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.eururo.2012.09.057","volume":"63","author":"AM Kamat","year":"2013","unstructured":"Kamat AM, Hegarty PK, Gee JR, Clark PE, Svatek RS, Hegarty N et al (2013) ICUD\u2013EAU international consultation on bladder cancer 2012: screening, diagnosis, and molecular markers. Eur Urol 63:4\u201315. https:\/\/doi.org\/10.1016\/j.eururo.2012.09.057","journal-title":"Eur Urol"},{"key":"2380_CR5","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/j.1464-410X.2010.09899.x","volume":"108","author":"J Messer","year":"2011","unstructured":"Messer J, Shariat SF, Brien JC, Herman MP, Ng CK, Scherr DS et al (2011) Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma. BJU Int 108:701\u2013705. https:\/\/doi.org\/10.1111\/j.1464-410X.2010.09899.x","journal-title":"BJU Int"},{"key":"2380_CR6","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1111\/j.1464-410X.2006.06036.x","volume":"97","author":"PI Karakiewicz","year":"2006","unstructured":"Karakiewicz PI, Benayoun S, Zippe C, L\u00fcdecke G, Boman H, Sanchez-Carbayo M et al (2006) Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder. BJU Int 97:997\u20131001. https:\/\/doi.org\/10.1111\/j.1464-410X.2006.06036.x","journal-title":"BJU Int"},{"key":"2380_CR7","doi-asserted-by":"publisher","first-page":"531.e15","DOI":"10.1016\/j.urolonc.2017.03.008","volume":"35","author":"Y Lotan","year":"2017","unstructured":"Lotan Y, O\u2019Sullivan P, Raman JD, Shariat SF, Kavalieris L, Frampton C et al (2017) Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma. Urol Oncol Semin Orig Investig 35:531.e15\u2013531.e22. https:\/\/doi.org\/10.1016\/j.urolonc.2017.03.008","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"2380_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2017.11.096","author":"S Daneshmand","year":"2017","unstructured":"Daneshmand S, Patel S, Lotan Y, Pohar K, Trabulsi E, Woods M et al (2017) Efficacy and safety of blue light flexible cystoscopy with hexaminolevulinate (HAL) in the surveillance of bladder cancer: a Phase III, comparative. Multi Center Study J Urol. https:\/\/doi.org\/10.1016\/j.juro.2017.11.096","journal-title":"Multi Center Study J Urol"},{"key":"2380_CR9","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.eururo.2011.05.053","volume":"60","author":"D Tilki","year":"2011","unstructured":"Tilki D, Burger M, Dalbagni G, Grossman HB, Hakenberg OW, Palou J et al (2011) Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. Eur Urol 60:484\u2013492. https:\/\/doi.org\/10.1016\/j.eururo.2011.05.053","journal-title":"Eur Urol"},{"key":"2380_CR10","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00345-018-2246-2","volume":"36","author":"N Lawrentschuk","year":"2018","unstructured":"Lawrentschuk N (2018) Evolution of technologies in urology: full steam ahead? World J Urol 36:517\u2013518. https:\/\/doi.org\/10.1007\/s00345-018-2246-2","journal-title":"World J Urol"},{"key":"2380_CR11","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.urolonc.2010.02.011","volume":"28","author":"SF Shariat","year":"2010","unstructured":"Shariat SF, Lotan Y, Vickers A, Karakiewicz PI, Schmitz-Drager BJ, Goebell PJ et al (2010) Statistical consideration for clinical biomarker research in bladder cancer. Urol Oncol 28:389\u2013400. https:\/\/doi.org\/10.1016\/j.urolonc.2010.02.011","journal-title":"Urol Oncol"},{"key":"2380_CR12","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1016\/j.eururo.2007.09.036","volume":"52","author":"K Bensalah","year":"2007","unstructured":"Bensalah K, Montorsi F, Shariat SF (2007) Challenges of cancer biomarker profiling. Eur Urol 52:1601\u20131609. https:\/\/doi.org\/10.1016\/j.eururo.2007.09.036","journal-title":"Eur Urol"},{"key":"2380_CR13","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.urolonc.2009.11.004","volume":"28","author":"Y Lotan","year":"2010","unstructured":"Lotan Y, Shariat SF, Schmitz-Drager BJ, Sanchez-Carbayo M, Jankevicius F, Racioppi M et al (2010) Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. Urol Oncol 28:441\u2013448. https:\/\/doi.org\/10.1016\/j.urolonc.2009.11.004","journal-title":"Urol Oncol"},{"key":"2380_CR14","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","volume":"196","author":"SS Chang","year":"2016","unstructured":"Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR et al (2016) Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline. J Urol 196:1021\u20131029. https:\/\/doi.org\/10.1016\/j.juro.2016.06.049","journal-title":"J Urol"},{"key":"2380_CR15","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1007\/s00345-014-1452-9","volume":"33","author":"C Seideman","year":"2015","unstructured":"Seideman C, Canter D, Kim P, Cordon B, Weizer A, Oliva I et al (2015) Multicenter evaluation of the role of UroVysion FISH assay in surveillance of patients with bladder cancer: does FISH positivity anticipate recurrence? World J Urol 33:1309\u20131313. https:\/\/doi.org\/10.1007\/s00345-014-1452-9","journal-title":"World J Urol"},{"key":"2380_CR16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ucl.2015.08.005","volume":"43","author":"A Mbeutcha","year":"2016","unstructured":"Mbeutcha A, Lucca I, Mathieu R, Lotan Y, Shariat SF (2016) Current status of urinary biomarkers for detection and surveillance of bladder cancer. Urol Clin North Am 43:47\u201362. https:\/\/doi.org\/10.1016\/j.ucl.2015.08.005","journal-title":"Urol Clin North Am"},{"key":"2380_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta14040","volume":"14","author":"G Mowatt","year":"2010","unstructured":"Mowatt G, Zhu S, Kilonzo M, Boachie C, Fraser C, Griffiths T et al (2010) Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. Health Technol Assess (Rockv) 14:1\u2013331. https:\/\/doi.org\/10.3310\/hta14040 (iii\u2013iv)","journal-title":"Health Technol Assess (Rockv)"},{"key":"2380_CR18","doi-asserted-by":"publisher","first-page":"66.e25","DOI":"10.1016\/j.urolonc.2014.06.008","volume":"33","author":"FA Yafi","year":"2015","unstructured":"Yafi FA, Brimo F, Steinberg J, Aprikian AG, Tanguay S, Kassouf W (2015) Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer. Urol Oncol Semin Orig Investig 33:66.e25\u201366.e31. https:\/\/doi.org\/10.1016\/j.urolonc.2014.06.008","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"2380_CR19","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s00345-016-1795-5","volume":"34","author":"MD Bell","year":"2016","unstructured":"Bell MD, Yafi FA, Brimo F, Steinberg J, Aprikian AG, Tanguay S et al (2016) Prognostic value of urinary cytology and other biomarkers for recurrence and progression in bladder cancer: a prospective study. World J Urol 34:1405\u20131409. https:\/\/doi.org\/10.1007\/s00345-016-1795-5","journal-title":"World J Urol"},{"key":"2380_CR20","doi-asserted-by":"publisher","first-page":"811","DOI":"10.7150\/ijms.19929","volume":"14","author":"R Pichler","year":"2017","unstructured":"Pichler R, Tulchiner G, Fritz J, Schaefer G, Horninger W, Heidegger I (2017) Urinary UBC Rapid and NMP22 Test for bladder cancer surveillance in comparison to urinary cytology: results from a prospective single-center study. Int J Med Sci 14:811\u2013819. https:\/\/doi.org\/10.7150\/ijms.19929","journal-title":"Int J Med Sci"},{"key":"2380_CR21","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1002\/cncr.25903","volume":"117","author":"SF Shariat","year":"2011","unstructured":"Shariat SF, Savage C, Chromecki TF, Sun M, Scherr DS, Lee RK et al (2011) Assessing the clinical benefit of nuclear matrix protein 22 in the surveillance of patients with nonmuscle-invasive bladder cancer and negative cytology: a decision-curve analysis. Cancer 117:2892\u20132897. https:\/\/doi.org\/10.1002\/cncr.25903","journal-title":"Cancer"},{"key":"2380_CR22","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1097\/01.ju.0000154696.48217.75","volume":"173","author":"SF Shariat","year":"2005","unstructured":"Shariat SF, Zippe C, L\u00fcdecke G, Boman H, Sanchez-Carbayo M, Casella R et al (2005) Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder. J Urol 173:1518\u20131525. https:\/\/doi.org\/10.1097\/01.ju.0000154696.48217.75","journal-title":"J Urol"},{"key":"2380_CR23","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.urology.2007.12.021","volume":"71","author":"M Babjuk","year":"2008","unstructured":"Babjuk M, Soukup V, Pe\u0161l M, Ko\u0161t\u00ed\u0159ov\u00e1 M, Drncov\u00e1 E, Smolov\u00e1 H et al (2008) Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pTapT1 bladder urothelial carcinoma. Urology 71:718\u2013722. https:\/\/doi.org\/10.1016\/j.urology.2007.12.021","journal-title":"Urology"},{"key":"2380_CR24","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00345-007-0230-3","volume":"26","author":"M-P Raitanen","year":"2008","unstructured":"Raitanen M-P (2008) FinnBladder group. The role of BTA stat test in follow-up of patients with bladder cancer: results from FinnBladder studies. World J Urol 26:45\u201350. https:\/\/doi.org\/10.1007\/s00345-007-0230-3","journal-title":"World J Urol"},{"key":"2380_CR25","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/cncr.10652","volume":"95","author":"VB Lokeshwar","year":"2002","unstructured":"Lokeshwar VB, Schroeder GL, Selzer MG, Hautmann SH, Posey JT, Duncan RC et al (2002) Bladder tumor markers for monitoring recurrence and screening comparison of hyaluronic acid-hyaluronidase and BTA-Stat tests. Cancer 95:61\u201372. https:\/\/doi.org\/10.1002\/cncr.10652","journal-title":"Cancer"},{"key":"2380_CR26","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S0022-5347(01)67054-X","volume":"154","author":"MF Sarosdy","year":"1995","unstructured":"Sarosdy MF, deVere White RW, Soloway MS, Sheinfeld J, Hudson MA, Schellhammer PF et al (1995) Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J Urol 154:379\u2013383 (discussion 383-4)","journal-title":"J Urol"},{"key":"2380_CR27","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.eururo.2011.08.073","volume":"61","author":"EK Cha","year":"2012","unstructured":"Cha EK, Tirsar LA, Schwentner C, Christos PJ, Mian C, Hennenlotter J et al (2012) Immunocytology is a strong predictor of bladder cancer presence in patients with painless hematuria: a multicentre study. Eur Urol 61:185\u2013192. https:\/\/doi.org\/10.1016\/j.eururo.2011.08.073","journal-title":"Eur Urol"},{"key":"2380_CR28","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/cncr.21712","volume":"108","author":"C Mian","year":"2006","unstructured":"Mian C, Maier K, Comploj E, Lodde M, Berner L, Lusuardi L et al (2006) uCyt\u2009+\/ImmunoCyt\u2122 in the detection of recurrent urothelial carcinoma. Cancer 108:60\u201365. https:\/\/doi.org\/10.1002\/cncr.21712","journal-title":"Cancer"},{"key":"2380_CR29","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1016\/j.juro.2008.01.105","volume":"179","author":"Y Lotan","year":"2008","unstructured":"Lotan Y, Bensalah K, Ruddell T, Shariat SF, Sagalowsky AI, Ashfaq R (2008) Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. J Urol 179:2164\u20132169. https:\/\/doi.org\/10.1016\/j.juro.2008.01.105","journal-title":"J Urol"},{"key":"2380_CR30","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.juro.2009.08.157","volume":"183","author":"BJ Schlomer","year":"2010","unstructured":"Schlomer BJ, Ho R, Sagalowsky A, Ashfaq R, Lotan Y (2010) Prospective validation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. J Urol 183:62\u201367. https:\/\/doi.org\/10.1016\/j.juro.2009.08.157","journal-title":"J Urol"},{"key":"2380_CR31","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","volume":"196","author":"SS Chang","year":"2016","unstructured":"Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR et al (2016) Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline. J Urol 196:1021\u20131029. https:\/\/doi.org\/10.1016\/j.juro.2016.06.049","journal-title":"J Urol"},{"key":"2380_CR32","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/bju.12516","volume":"114","author":"PH Kim","year":"2014","unstructured":"Kim PH, Sukhu R, Cordon BH, Sfakianos JP, Sjoberg DD, Hakimi AA et al (2014) Reflex fluorescence in situ hybridization assay for suspicious urinary cytology in patients with bladder cancer with negative surveillance cystoscopy. BJU Int 114:354\u2013359. https:\/\/doi.org\/10.1111\/bju.12516 (n\/a-n\/a)","journal-title":"BJU Int"},{"key":"2380_CR33","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.juro.2013.03.117","volume":"190","author":"BA Gayed","year":"2013","unstructured":"Gayed BA, Seideman C, Lotan Y (2013) Cost-effectiveness of fluorescence in situ hybridization in patients with atypical cytology for the detection of urothelial carcinoma. J Urol 190:1181\u20131186. https:\/\/doi.org\/10.1016\/j.juro.2013.03.117","journal-title":"J Urol"},{"key":"2380_CR34","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/j.juro.2016.12.010","volume":"197","author":"L Kavalieris","year":"2017","unstructured":"Kavalieris L, O\u2019Sullivan P, Frampton C, Guilford P, Darling D, Jacobson E et al (2017) Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study. J Urol 197:1419\u20131426. https:\/\/doi.org\/10.1016\/j.juro.2016.12.010","journal-title":"J Urol"},{"key":"2380_CR35","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/bju.14019","volume":"121","author":"R Pichler","year":"2018","unstructured":"Pichler R, Fritz J, Tulchiner G, Klinglmair G, Soleiman A, Horninger W et al (2018) Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance. BJU Int 121:29\u201337. https:\/\/doi.org\/10.1111\/bju.14019","journal-title":"BJU Int"},{"key":"2380_CR36","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1002\/cncr.21795","volume":"106","author":"RS Svatek","year":"2006","unstructured":"Svatek RS, Herman MP, Lotan Y, Casella R, Hsieh J-T, Sagalowsky AI et al (2006) Soluble fas\u2014a promising novel urinary marker for the detection of recurrent superficial bladder cancer. Cancer 106:1701\u20131707. https:\/\/doi.org\/10.1002\/cncr.21795","journal-title":"Cancer"},{"key":"2380_CR37","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1159\/000350752","volume":"91","author":"H Yang","year":"2013","unstructured":"Yang H, Li H, Wang Z, Gao J, Guo Y (2013) Is urinary soluble fas an independent predictor of non-muscle-invasive bladder cancer? A prospective chart study. Urol Int 91:456\u2013461. https:\/\/doi.org\/10.1159\/000350752","journal-title":"Urol Int"},{"key":"2380_CR38","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.eururo.2009.03.057","volume":"57","author":"MW Kramer","year":"2010","unstructured":"Kramer MW, Golshani R, Merseburger AS, Knapp J, Garcia A, Hennenlotter J et al (2010) HYAL-1 hyaluronidase: a potential prognostic indicator for progression to muscle invasion and recurrence in bladder cancer. Eur Urol 57:86\u201394. https:\/\/doi.org\/10.1016\/j.eururo.2009.03.057","journal-title":"Eur Urol"},{"key":"2380_CR39","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1097\/01.ju.0000107826.78479.90","volume":"171","author":"SF Shariat","year":"2004","unstructured":"Shariat SF, Casella R, Khoddami SM, Hernandez G, Sulser T, Gasser TC et al (2004) Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol 171:626\u2013630. https:\/\/doi.org\/10.1097\/01.ju.0000107826.78479.90","journal-title":"J Urol"},{"key":"2380_CR40","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1002\/cncr.22521","volume":"109","author":"SF Shariat","year":"2007","unstructured":"Shariat SF, Ashfaq R, Karakiewicz PI, Saeedi O, Sagalowsky AI, Lotan Y (2007) Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer 109:1106\u20131113. https:\/\/doi.org\/10.1002\/cncr.22521","journal-title":"Cancer"},{"key":"2380_CR41","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1186\/1471-2407-10-646","volume":"10","author":"AS Brems-Eskildsen","year":"2010","unstructured":"Brems-Eskildsen AS, Zieger K, Toldbod H, Holcomb C, Higuchi R, Mansilla F et al (2010) Prediction and diagnosis of bladder cancer recurrence based on urinary content of hTERT, SENP1, PPP1CA, and MCM5 transcripts. BMC Cancer 10:646. https:\/\/doi.org\/10.1186\/1471-2407-10-646","journal-title":"BMC Cancer"},{"key":"2380_CR42","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1016\/S0002-9440(10)64665-2","volume":"158","author":"C Billerey","year":"2001","unstructured":"Billerey C, Chopin D, Aubriot-Lorton MH, Ricol D, Diez Gil, de Medina S, Van Rhijn B et al (2001) Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol 158:1955\u20131959. https:\/\/doi.org\/10.1016\/S0002-9440(10)64665-2","journal-title":"Am J Pathol"},{"key":"2380_CR43","first-page":"1265","volume":"61","author":"BW Rhijn van","year":"2001","unstructured":"van Rhijn BW, Lurkin I, Radvanyi F, Kirkels WJ, van der Kwast TH, Zwarthoff EC (2001) The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 61:1265\u20131268","journal-title":"Cancer Res"},{"key":"2380_CR44","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1158\/1078-0432.CCR-09-3013","volume":"16","author":"TCM Zuiverloon","year":"2010","unstructured":"Zuiverloon TCM, van der Aa MNM, van der Kwast TH, Steyerberg EW, Lingsma HF, Bangma CH et al (2010) Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer. Clin Cancer Res 16:3011\u20133018. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-3013","journal-title":"Clin Cancer Res"},{"key":"2380_CR45","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1158\/1078-0432.CCR-13-2637","volume":"20","author":"S-F Su","year":"2014","unstructured":"Su S-F, de Castro Abreu AL, Chihara Y, Tsai Y, Andreu-Vieyra C, Daneshmand S et al (2014) A panel of three markers hyper- and hypomethylated in urine sediments accurately predicts bladder cancer recurrence. Clin Cancer Res 20:1978\u20131989. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-2637","journal-title":"Clin Cancer Res"},{"key":"2380_CR46","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.juro.2007.10.026","volume":"179","author":"C-L Ho","year":"2008","unstructured":"Ho C-L, Tzai T-S, Chen J-C, Tsai H-W, Cheng H-L, Eisenberger CF et al (2008) the molecular signature for urothelial carcinoma of the upper urinary tract. J Urol 179:1155\u20131159. https:\/\/doi.org\/10.1016\/j.juro.2007.10.026","journal-title":"J Urol"},{"key":"2380_CR47","doi-asserted-by":"publisher","first-page":"5218","DOI":"10.18632\/oncotarget.2129","volume":"5","author":"L Maldonado","year":"2014","unstructured":"Maldonado L, Brait M, Michailidi C, Munari E, Driscoll T, Schultz L et al (2014) An epigenetic marker panel for recurrence risk prediction of low grade papillary urothelial cell carcinoma (LGPUCC) and its potential use for surveillance after transurethral resection using urine. Oncotarget 5:5218\u20135233. https:\/\/doi.org\/10.18632\/oncotarget.2129","journal-title":"Oncotarget"},{"key":"2380_CR48","doi-asserted-by":"publisher","first-page":"51.e21","DOI":"10.1016\/j.urolonc.2013.08.003","volume":"32","author":"MR Abern","year":"2014","unstructured":"Abern MR, Owusu R, Inman BA (2014) Clinical performance and utility of a DNA methylation urine test for bladder cancer11This study was funded, in part, by MDxHealth (formerly OncoMethlyome sciences). Urol Oncol Semin Orig Investig 32:51.e21\u201351.e26. https:\/\/doi.org\/10.1016\/j.urolonc.2013.08.003","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"2380_CR49","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1016\/j.juro.2016.12.096","volume":"197","author":"W Beukers","year":"2017","unstructured":"Beukers W, van der Keur KA, Kandimalla R, Vergouwe Y, Steyerberg EW, Boormans JL et al (2017) FGFR3, TERT and OTX1 as a urinary biomarker combination for surveillance of patients with bladder cancer in a large prospective multicenter study. J Urol 197:1410\u20131418. https:\/\/doi.org\/10.1016\/j.juro.2016.12.096","journal-title":"J Urol"},{"key":"2380_CR50","doi-asserted-by":"publisher","first-page":"4760","DOI":"10.1158\/1078-0432.CCR-12-3276","volume":"19","author":"R Kandimalla","year":"2013","unstructured":"Kandimalla R, Masius R, Beukers W, Bangma CH, Orntoft TF, Dyrskjot L et al (2013) A 3-plex methylation assay combined with the FGFR3 mutation assay sensitively detects recurrent bladder cancer in voided urine. Clin Cancer Res 19:4760\u20134769. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-3276","journal-title":"Clin Cancer Res"},{"key":"2380_CR51","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1186\/s12885-016-2748-5","volume":"16","author":"J-P Roperch","year":"2016","unstructured":"Roperch J-P, Grandchamp B, Desgrandchamps F, Mongiat-Artus P, Ravery V, Ouzaid I et al (2016) Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive\/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer. BMC Cancer 16:704. https:\/\/doi.org\/10.1186\/s12885-016-2748-5","journal-title":"BMC Cancer"},{"key":"2380_CR52","doi-asserted-by":"publisher","first-page":"101042831769755","DOI":"10.1177\/1010428317697552","volume":"39","author":"N Kumari","year":"2017","unstructured":"Kumari N, Agrawal U, Mishra AK, Kumar A, Vasudeva P, Mohanty NK et al (2017) Predictive role of serum and urinary cytokines in invasion and recurrence of bladder cancer. Tumor Biol 39:101042831769755. https:\/\/doi.org\/10.1177\/1010428317697552","journal-title":"Tumor Biol"},{"key":"2380_CR53","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.eururo.2008.05.001","volume":"55","author":"MNM Aa van der","year":"2009","unstructured":"van der Aa MNM, Zwarthoff EC, Steyerberg EW, Boogaard MW, Nijsen Y, van der Keur KA et al (2009) Microsatellite Analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study [cost-effectiveness of follow-up of urinary bladder cancer trial (CEFUB)]. Eur Urol 55:659\u2013668. https:\/\/doi.org\/10.1016\/j.eururo.2008.05.001","journal-title":"Eur Urol"},{"key":"2380_CR54","doi-asserted-by":"publisher","first-page":"7369","DOI":"10.1158\/1078-0432.CCR-06-1472","volume":"12","author":"V Margulis","year":"2006","unstructured":"Margulis V, Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y (2006) Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease. Clin Cancer Res 12:7369\u20137373. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-1472","journal-title":"Clin Cancer Res"},{"key":"2380_CR55","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s10147-016-1068-8","volume":"22","author":"T Kojima","year":"2017","unstructured":"Kojima T, Kawai K, Miyazaki J, Nishiyama H (2017) Biomarkers for precision medicine in bladder cancer. Int J Clin Oncol 22:207\u2013213. https:\/\/doi.org\/10.1007\/s10147-016-1068-8","journal-title":"Int J Clin Oncol"},{"key":"2380_CR56","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrurol.2014.15","volume":"11","author":"G Redelman-Sidi","year":"2014","unstructured":"Redelman-Sidi G, Glickman MS, Bochner BH (2014) The mechanism of action of BCG therapy for bladder cancer\u2014a current perspective. Nat Rev Urol 11:153\u2013162. https:\/\/doi.org\/10.1038\/nrurol.2014.15","journal-title":"Nat Rev Urol"},{"key":"2380_CR57","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1002\/ijc.24258","volume":"124","author":"S Savic","year":"2009","unstructured":"Savic S, Zlobec I, Thalmann GN, Engeler D, Schmauss M, Lehmann K et al (2009) The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Gu\u00e9rin therapy. Int J Cancer 124:2899\u20132904. https:\/\/doi.org\/10.1002\/ijc.24258","journal-title":"Int J Cancer"},{"key":"2380_CR58","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1111\/bju.13186","volume":"117","author":"AM Kamat","year":"2016","unstructured":"Kamat AM, Willis DL, Dickstein RJ, Anderson R, Nogueras-Gonz\u00e1lez G, Katz RL et al (2016) Novel fluorescence in\u00a0situ hybridization-based definition of Bacille Calmette-Gu\u00e9rin (BCG) failure for use in enhancing recruitment into clinical trials of intravesical therapies. BJU Int 117:754\u2013760. https:\/\/doi.org\/10.1111\/bju.13186","journal-title":"BJU Int"},{"key":"2380_CR59","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.eururo.2015.06.023","volume":"69","author":"AM Kamat","year":"2016","unstructured":"Kamat AM, Briggman J, Urbauer DL, Svatek R, Nogueras Gonz\u00e1lez GM, Anderson R et al (2016) Cytokine panel for response to intravesical therapy (CyPRIT): nomogram of changes in urinary cytokine levels predicts patient response to Bacillus Calmette-Gu\u00e9rin. Eur Urol 69:197\u2013200. https:\/\/doi.org\/10.1016\/j.eururo.2015.06.023","journal-title":"Eur Urol"},{"key":"2380_CR60","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/S0022-5347(05)65469-9","volume":"167","author":"F Saint","year":"2002","unstructured":"Saint F, Patard JJ, Maille P, Soyeux P, Hoznek A, Salomon L et al (2002) Prognostic value of a T helper 1 urinary cytokine response after intravesical Bacillus Calmette-Guerin treatment for superficial bladder cancer. J Urol 167:364\u2013367","journal-title":"J Urol"},{"key":"2380_CR61","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00262-003-0384-9","volume":"52","author":"E Watanabe","year":"2003","unstructured":"Watanabe E, Matsuyama H, Matsuda K, Ohmi C, Tei Y, Yoshihiro S et al (2003) Urinary interleukin-2 may predict clinical outcome of intravesical Bacillus Calmette-Gu\u00e9rin immunotherapy for carcinoma in situ of the bladder. Cancer Immunol Immunother 52:481\u2013486. https:\/\/doi.org\/10.1007\/s00262-003-0384-9","journal-title":"Cancer Immunol Immunother"},{"key":"2380_CR62","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/S0022-5347(01)66424-3","volume":"155","author":"TM Reijke de","year":"1996","unstructured":"de Reijke TM, de Boer EC, Kurth KH, Schamhart DH (1996) Urinary cytokines during intravesical Bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value. J Urol 155:477\u2013482","journal-title":"J Urol"},{"key":"2380_CR63","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1016\/S0022-5347(05)66983-2","volume":"164","author":"GN Thalmann","year":"2000","unstructured":"Thalmann GN, Sermier A, Rentsch C, M\u00f6hrle K, Cecchini MG, Studer UE (2000) Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with Bacillus Calmette-Guerin. J Urol 164:2129\u20132133","journal-title":"J Urol"},{"key":"2380_CR64","doi-asserted-by":"publisher","first-page":"E16","DOI":"10.3816\/CGC.2009.n.016","volume":"7","author":"L Sagnak","year":"2009","unstructured":"Sagnak L, Ersoy H, Ozok U, Senturk B, Ercil H, Bahar G et al (2009) Predictive value of urinary interleukin-8 cutoff point for recurrences after transurethral resection plus induction Bacillus Calmette-Gu\u00e9rin treatment in non-muscle-invasive bladder tumors. Clin Genitourin Cancer 7:E16\u2013E23. https:\/\/doi.org\/10.3816\/CGC.2009.n.016","journal-title":"Clin Genitourin Cancer"},{"key":"2380_CR65","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3892\/etm.2012.634","volume":"4","author":"T Cai","year":"2012","unstructured":"Cai T, Nesi G, Mazzoli S, Meacci F, Tinacci G, Luciani LG et al (2012) Prediction of response to Bacillus Calmette-Gu\u00e9rin treatment in non-muscle invasive bladder cancer patients through interleukin-6 and interleukin-10 ratio. Exp Ther Med 4:459\u2013464. https:\/\/doi.org\/10.3892\/etm.2012.634","journal-title":"Exp Ther Med"},{"key":"2380_CR66","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/S0210-4806(05)73235-6","volume":"29","author":"C Aguilera Tubet","year":"2005","unstructured":"Aguilera Tubet C, Guti\u00e9rrez Ba\u00f1os JL, Antol\u00edn Ju\u00e1rez F, Rebollo Rodrigo MH, Portillo Mart\u00edn JA, Ruiz Izquierdo F et al (2005) Comparative study between cystoscopy, urinary cytology, NMP-22 and a new method, bladder chek, in the follow-up of superficial bladder cell carcinoma. Actas Urol Esp 29:252\u2013256","journal-title":"Actas Urol Esp"},{"key":"2380_CR67","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1001\/jama.295.3.299","volume":"295","author":"HB Grossman","year":"2006","unstructured":"Grossman HB, Soloway M, Messing E, Katz G, Stein B, Kassabian V et al (2006) Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA 295:299. https:\/\/doi.org\/10.1001\/jama.295.3.299","journal-title":"JAMA"},{"key":"2380_CR68","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1093\/jjco\/hyi244","volume":"36","author":"A Kumar","year":"2006","unstructured":"Kumar A, Kumar R, Gupta NP (2006) Comparison of NMP22 bladder chek test and urine cytology for the detection of recurrent bladder cancer. Jpn J Clin Oncol 36:172\u2013175. https:\/\/doi.org\/10.1093\/jjco\/hyi244","journal-title":"Jpn J Clin Oncol"},{"key":"2380_CR69","first-page":"377","volume":"61","author":"V Gonzalo Rodr\u00edguez","year":"2008","unstructured":"Gonzalo Rodr\u00edguez V, Sanz Justo L, de Miguel Santamar\u00eda I, Mart\u00ednez de Iturrate J, Fern\u00e1ndez del Busto E (2008) The use of NMP22 Bladder-Chek for the diagnosis and follow-up bladder cancer. Arch Esp Urol 61:377\u2013384","journal-title":"Arch Esp Urol"},{"key":"2380_CR70","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.urology.2008.04.051","volume":"73","author":"NP Gupta","year":"2009","unstructured":"Gupta NP, Sharma N, Kumar R (2009) Nuclear matrix protein 22 as adjunct to urine cytology and cystoscopy in follow-up of superficial TCC of urinary bladder. Urology 73:592\u2013596. https:\/\/doi.org\/10.1016\/j.urology.2008.04.051","journal-title":"Urology"},{"key":"2380_CR71","first-page":"1279","volume":"11","author":"VK Kundal","year":"2010","unstructured":"Kundal VK, Pandith AA, Hamid A, Shah A, Kundal R, Wani SM (2010) Role of NMP22 bladder check test in early detection of bladder cancer with recurrence. Asian Pac J Cancer Prev 11:1279\u20131282","journal-title":"Asian Pac J Cancer Prev"},{"key":"2380_CR72","doi-asserted-by":"publisher","first-page":"88","DOI":"10.4111\/kju.2010.51.2.88","volume":"51","author":"HS Choi","year":"2010","unstructured":"Choi HS, Lee SI, Kim DJ, Jeong TY (2010) Usefulness of the NMP22BladderChek test for screening and follow-up of bladder cancer. Korean J Urol 51:88. https:\/\/doi.org\/10.4111\/kju.2010.51.2.88","journal-title":"Korean J Urol"},{"key":"2380_CR73","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.urology.2010.04.059","volume":"77","author":"EC Hwang","year":"2011","unstructured":"Hwang EC, Choi HS, Jung S Il, Kwon DD, Park K, Ryu SB (2011) Use of the NMP22 BladderChek test in the diagnosis and follow-up of urothelial cancer: a cross-sectional study. Urology 77:154\u2013159. https:\/\/doi.org\/10.1016\/j.urology.2010.04.059","journal-title":"Urology"},{"key":"2380_CR74","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s11255-012-0144-x","volume":"44","author":"E Coskuner","year":"2012","unstructured":"Coskuner E, Cevik I, Ozkan A, Dillioglugil O, Akdas A (2012) In the cystoscopic follow-up of non-muscle-invasive transitional cell carcinoma, NMP-22 works for high grades, but unreliable in low grades and upper urinary tract tumors. Int Urol Nephrol 44:793\u2013798. https:\/\/doi.org\/10.1007\/s11255-012-0144-x","journal-title":"Int Urol Nephrol"},{"key":"2380_CR75","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/dc.23239","volume":"43","author":"B \u00d6nal","year":"2015","unstructured":"\u00d6nal B, Han \u00dc, Yilmaz S, K\u00f6ybasioglu F, Altu\u011f U (2015) The use of urinary nuclear matrix protein 22 (NMP22) as a diagnostic adjunct to urine cytology for monitoring of recurrent bladder cancer-institutional experience and review. Diagn Cytopathol 43:307\u2013314. https:\/\/doi.org\/10.1002\/dc.23239","journal-title":"Diagn Cytopathol"},{"key":"2380_CR76","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/S0090-4295(98)00332-X","volume":"52","author":"V Serretta","year":"1998","unstructured":"Serretta V, Lo Presti D, Vasile P, Gange E, Esposito E, Menozzi I (1998) Urinary NMP22 for the detection of recurrence after transurethral resection of transitional cell carcinoma of the bladder: experience on 137 patients. Urology 52:793\u2013796","journal-title":"Urology"},{"key":"2380_CR77","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1159\/000019621","volume":"33","author":"JA Witjes","year":"1998","unstructured":"Witjes JA, van der Poel HG, van Balken MR, Debruyne FM, Schalken JA (1998) Urinary NMP22 and karyometry in the diagnosis and follow-up of patients with superficial bladder cancer. Eur Urol 33:387\u2013391","journal-title":"Eur Urol"},{"key":"2380_CR78","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1159\/000020318","volume":"38","author":"V Serretta","year":"2000","unstructured":"Serretta V, Pomara G, Rizzo I, Esposito E (2000) Urinary BTA-stat, BTA-trak and NMP22 in surveillance after TUR of recurrent superficial transitional cell carcinoma of the bladder. Eur Urol 38:419\u2013425 (doi:20318)","journal-title":"Eur Urol"},{"key":"2380_CR79","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1159\/000049809","volume":"40","author":"R Chahal","year":"2001","unstructured":"Chahal R, Darshane A, Browning AJ, Sundaram SK (2001) Evaluation of the clinical value of urinary NMP22 as a marker in the screening and surveillance of transitional cell carcinoma of the urinary bladder. Eur Urol 40:415\u2013420 (discussion 421)","journal-title":"Eur Urol"},{"key":"2380_CR80","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/S0022-5347(05)65965-4","volume":"166","author":"A Giannopoulos","year":"2001","unstructured":"Giannopoulos A, Manousakas T, Gounari A, Constantinides C, Choremi-Papadopoulou H, Dimopoulos C (2001) Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors. J Urol 166:470\u2013475","journal-title":"J Urol"},{"key":"2380_CR81","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.eururo.2003.10.020","volume":"45","author":"SF Shariat","year":"2004","unstructured":"Shariat SF, Casella R, Wians FH, Ashfaq R, Balko J, Sulser T et al (2004) Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology. Eur Urol 45:304\u2013313. https:\/\/doi.org\/10.1016\/j.eururo.2003.10.020","journal-title":"Eur Urol"},{"key":"2380_CR82","first-page":"111","volume":"539","author":"S Lahme","year":"2003","unstructured":"Lahme S, Bichler K-H, Feil G, Zumbr\u00e4gel A, G\u00f6tz T (2003) Comparison of cytology and nuclear matrix protein 22 (NMP 22) for the detection and follow-up of bladder-cancer. Adv Exp Med Biol 539:111\u2013119","journal-title":"Adv Exp Med Biol"},{"key":"2380_CR83","first-page":"31","volume":"36","author":"Y Kibar","year":"2006","unstructured":"Kibar Y, Goktas S, Kilic S, Yaman H, Onguru O, Peker AF (2006) Prognostic value of cytology, nuclear matrix protein 22 (NMP22) test, and urinary bladder cancer II (UBC II) test in early recurrent transitional cell carcinoma of the bladder. Ann Clin Lab Sci 36:31\u201338","journal-title":"Ann Clin Lab Sci"},{"key":"2380_CR84","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/j.1464-410X.2008.07789.x","volume":"102","author":"R Raina","year":"2008","unstructured":"Raina R, Pahlajani G, Ponsky LE, Agarwal A, Zippe CD (2008) The clinical utility of atypical cytology is significantly increased in both screening and monitoring for bladder cancer when indexed with nuclear matrix protein-22. BJU Int 102:297\u2013300. https:\/\/doi.org\/10.1111\/j.1464-410X.2008.07789.x","journal-title":"BJU Int"},{"key":"2380_CR85","first-page":"25","volume":"30","author":"I Mansoor","year":"2008","unstructured":"Mansoor I, Calam RR, Al-Khafaji B (2008) Role of urinary NMP-22 combined with urine cytology in follow-up surveillance of recurring superficial bladder urothelial carcinoma. Anal Quant Cytol Histol 30:25\u201332","journal-title":"Anal Quant Cytol Histol"},{"key":"2380_CR86","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3109\/00365590903296837","volume":"43","author":"M Horstmann","year":"2009","unstructured":"Horstmann M, Patschan O, Hennenlotter J, Senger E, Feil G, Stenzl A (2009) Combinations of urine-based tumour markers in bladder cancer surveillance. Scand J Urol Nephrol 43:461\u2013466. https:\/\/doi.org\/10.3109\/00365590903296837","journal-title":"Scand J Urol Nephrol"},{"key":"2380_CR87","doi-asserted-by":"publisher","first-page":"137","DOI":"10.5152\/tud.2013.029","volume":"39","author":"C Dogan","year":"2014","unstructured":"Dogan C, Pelit ES, Yildirim A, Ebru Zemheri I, Canakci C, Kaan Ba\u015fok E et al (2014) The value of the NMP22 test for superficial bladder cancer diagnosis and follow-up. T\u00fcrk \u00dcroloji Dergisi\/Turkish J Urol 39:137\u2013142. https:\/\/doi.org\/10.5152\/tud.2013.029","journal-title":"T\u00fcrk \u00dcroloji Dergisi\/Turkish J Urol"},{"key":"2380_CR88","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S0090-4295(97)00081-2","volume":"49","author":"A Ianari","year":"1997","unstructured":"Ianari A, Sternberg CN, Rossetti A, Van Rijn A, Deidda A, Giannarelli D et al (1997) Results of Bard BTA test in monitoring patients with a history of transitional cell cancer of the bladder. Urology 49:786\u2013789. https:\/\/doi.org\/10.1016\/S0090-4295(97)00081-2","journal-title":"Urology"},{"key":"2380_CR89","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1159\/000480801","volume":"32","author":"H Leyh","year":"1997","unstructured":"Leyh H, Mazeman E (1997) Bard BTA test compared with voided urine cytology in the diagnosis of recurrent bladder cancer. Eur Urol 32:425\u2013428","journal-title":"Eur Urol"},{"key":"2380_CR90","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1046\/j.1464-410X.1997.d01-6879.x","volume":"79","author":"MM Kirollos","year":"1997","unstructured":"Kirollos MM (1997) The use of the bladder-tumour associated analyte test to determine the type of cystoscopy in the follow-up of patients with bladder cancer. The United Kingdom and Eire Bladder tumour antigen study group. Br J Urol 79:362\u2013366","journal-title":"Br J Urol"},{"key":"2380_CR91","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/S0090-4295(97)00292-6","volume":"50","author":"MF Sarosdy","year":"1997","unstructured":"Sarosdy MF, Hudson MA, Ellis WJ, Soloway MS, deVere White R, Sheinfeld J et al (1997) Improved detection of recurrent bladder cancer using the bard BTA stat test. Urology 50:349\u2013353","journal-title":"Urology"},{"key":"2380_CR92","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1097\/01.ju.0000034254.89258.8e","volume":"168","author":"MF Sarosdy","year":"2002","unstructured":"Sarosdy MF, Schellhammer P, Bokinsky G, Kahn P, Chao R, Yore L et al (2002) Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol 168:1950\u20131954. https:\/\/doi.org\/10.1097\/01.ju.0000034254.89258.8e","journal-title":"J Urol"},{"key":"2380_CR93","first-page":"856","volume":"52","author":"JL Guti\u00e9rrez Ba\u00f1os","year":"1999","unstructured":"Guti\u00e9rrez Ba\u00f1os JL, Mart\u00edn Garc\u00eda B, de Diego Rodr\u00edguez E, Hern\u00e1ndez Rodr\u00edguez R, Portillo Mart\u00edn JA, Correas G\u00f3mez MA et al (1999) The BTA stat test in the follow-up for bladder cancer. Arch Esp Urol 52:856\u2013861","journal-title":"Arch Esp Urol"},{"key":"2380_CR94","first-page":"41","volume":"55","author":"JM Fern\u00e1ndez G\u00f3mez","year":"2002","unstructured":"Fern\u00e1ndez G\u00f3mez JM, Garc\u00eda Rodr\u00edguez J, Escaf Barmadah S, Raigoso P, Rodr\u00edguez Mart\u00ednez JJ, Allende MT et al (2002) Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma. Arch Esp Urol 55:41\u201349 (n.d.)","journal-title":"Arch Esp Urol"},{"key":"2380_CR95","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S0090-4295(01)01217-1","volume":"58","author":"JL Vriesema","year":"2001","unstructured":"Vriesema JL, Atsma F, Kiemeney LA, Peelen WP, Witjes JA, Schalken JA (2001) Diagnostic efficacy of the ImmunoCyt test to detect superficial bladder cancer recurrence. Urology 58:367\u2013371","journal-title":"Urology"},{"key":"2380_CR96","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1097\/01.ju.0000048983.83079.4c","volume":"169","author":"C Pfister","year":"2003","unstructured":"Pfister C, Chautard D, Devonec M, Perrin P, Chopin D, Rischmann P et al (2003) Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study. J Urol 169:921\u2013924. https:\/\/doi.org\/10.1097\/01.ju.0000048983.83079.4c","journal-title":"J Urol"},{"key":"2380_CR97","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/modpathol.3800262","volume":"18","author":"B T\u00eatu","year":"2005","unstructured":"T\u00eatu B, Tiguert R, Harel F, Fradet Y (2005) ImmunoCyt\/uCyt\u2009+\u2009\u2122 improves the sensitivity of urine cytology in patients followed for urothelial carcinoma. Mod Pathol 18:83\u201389. https:\/\/doi.org\/10.1038\/modpathol.3800262","journal-title":"Mod Pathol"},{"key":"2380_CR98","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1097\/01.ju.0000173918.84006.4d","volume":"174","author":"EM Messing","year":"2005","unstructured":"Messing EM, Teot L, Korman H, Underhill E, Barker E, Stork B et al (2005) Performance of urine test in patients monitored for recurrence of bladder cancer: a multicenter study in the United States. J Urol 174:1238\u20131241","journal-title":"J Urol"},{"key":"2380_CR99","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.urology.2005.11.057","volume":"67","author":"M Lodde","year":"2006","unstructured":"Lodde M, Mian C, Comploj E, Palermo S, Longhi E, Marberger M et al (2006) uCyt\u2009+\u2009test: alternative to cystoscopy for less-invasive follow-up of patients with low risk of urothelial carcinoma. Urology 67:950\u2013954. https:\/\/doi.org\/10.1016\/j.urology.2005.11.057","journal-title":"Urology"},{"key":"2380_CR100","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/cncy.20026","volume":"117","author":"PS Sullivan","year":"2009","unstructured":"Sullivan PS, Nooraie F, Sanchez H, Hirschowitz S, Levin M, Rao PN et al (2009) Comparison of ImmunoCyt, UroVysion, and urine cytology in detection of recurrent urothelial carcinoma. Cancer Cytopathol 117:167\u2013173. https:\/\/doi.org\/10.1002\/cncy.20026","journal-title":"Cancer Cytopathol"},{"key":"2380_CR101","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/S1078-1439(03)00098-X","volume":"22","author":"M Varella-Garcia","year":"2004","unstructured":"Varella-Garcia M, Akduman B, Sunpaweravong P, Di Maria MV, Crawford ED (2004) The UroVysion fluorescence in situ hybridization assay is an effective tool for monitoring recurrence of bladder cancer. Urol Oncol Semin Orig Investig 22:16\u201319. https:\/\/doi.org\/10.1016\/S1078-1439(03)00098-X","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"2380_CR102","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.urology.2003.10.020","volume":"63","author":"A Pycha","year":"2004","unstructured":"Pycha A, Lodde M, Comploj E, Negri G, Egarter-Vigl E, Vittadello F et al (2004) Intermediate-risk urothelial carcinoma: an unresolved problem? Urology 63:472\u2013475. https:\/\/doi.org\/10.1016\/j.urology.2003.10.020","journal-title":"Urology"},{"key":"2380_CR103","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/01.ju.0000149825.83180.a4","volume":"173","author":"B Kipp","year":"2005","unstructured":"Kipp B, Karnes R, Brankley S, Harwood A, Pankratz V, Sebo T et al (2005) Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization. J Urol 173:401\u2013404. https:\/\/doi.org\/10.1097\/01.ju.0000149825.83180.a4","journal-title":"J Urol"},{"key":"2380_CR104","doi-asserted-by":"publisher","first-page":"070915222359021","DOI":"10.1111\/j.1464-410x.2007.07183.x","volume":"0","author":"J Bergman","year":"2007","unstructured":"Bergman J, Reznichek RC, Rajfer J (2007) Surveillance of patients with bladder carcinoma using fluorescent in situ hybridization on bladder washings. BJU Int 0:070915222359021. https:\/\/doi.org\/10.1111\/j.1464-410x.2007.07183.x","journal-title":"BJU Int"},{"key":"2380_CR105","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.eururo.2006.10.044","volume":"51","author":"PMJ Moonen","year":"2007","unstructured":"Moonen PMJ, Merkx GFM, Peelen P, Karthaus HFM, Smeets DFCM, Witjes JA (2007) UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer. Eur Urol 51:1275\u20131280. https:\/\/doi.org\/10.1016\/j.eururo.2006.10.044 (discussion 1280)","journal-title":"Eur Urol"},{"key":"2380_CR106","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1309\/ADJL7E810U1H42BJ","volume":"127","author":"BJ Yoder","year":"2007","unstructured":"Yoder BJ, Skacel M, Hedgepeth R, Babineau D, Ulchaker JC, Liou LS et al (2007) Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology. Am J Clin Pathol 127:295\u2013301. https:\/\/doi.org\/10.1309\/ADJL7E810U1H42BJ","journal-title":"Am J Clin Pathol"},{"key":"2380_CR107","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.eururo.2007.11.051","volume":"54","author":"S Gudj\u00f3nsson","year":"2008","unstructured":"Gudj\u00f3nsson S, Isfoss BL, Hansson K, Domanski A-M, Warenholt J, Soller W et al (2008) The value of the UroVysion\u00ae assay for surveillance of non-muscle-invasive bladder cancer. Eur Urol 54:402\u2013408. https:\/\/doi.org\/10.1016\/j.eururo.2007.11.051","journal-title":"Eur Urol"},{"key":"2380_CR108","first-page":"5077","volume":"17","author":"A Karnwal","year":"2010","unstructured":"Karnwal A, Venegas R, Shuch B, Bassett J, Rajfer J, Reznichek R (2010) The role of fluorescence in situ hybridization assay for surveillance of non-muscle invasive bladder cancer. Can J Urol 17:5077\u20135081","journal-title":"Can J Urol"},{"key":"2380_CR109","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1309\/AJCPKKWBDSAOZ4RW","volume":"134","author":"H-M Fritsche","year":"2010","unstructured":"Fritsche H-M, Burger M, Dietmaier W, Denzinger S, Bach E, Otto W et al (2010) Multicolor FISH (UroVysion) facilitates follow-up of patients with high-grade urothelial carcinoma of the bladder. Am J Clin Pathol 134:597\u2013603. https:\/\/doi.org\/10.1309\/AJCPKKWBDSAOZ4RW","journal-title":"Am J Clin Pathol"},{"key":"2380_CR110","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.urolonc.2010.02.012","volume":"30","author":"RF Youssef","year":"2012","unstructured":"Youssef RF, Schlomer BJ, Ho R, Sagalowsky AI, Ashfaq R, Lotan Y (2012) Role of fluorescence in situ hybridization in bladder cancer surveillance of patients with negative cytology. Urol Oncol Semin Orig Investig 30:273\u2013277. https:\/\/doi.org\/10.1016\/j.urolonc.2010.02.012","journal-title":"Urol Oncol Semin Orig Investig"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00345-018-2380-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-018-2380-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-018-2380-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,19]],"date-time":"2019-10-19T16:35:31Z","timestamp":1571502931000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00345-018-2380-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,21]]},"references-count":110,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["2380"],"URL":"https:\/\/doi.org\/10.1007\/s00345-018-2380-x","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,21]]},"assertion":[{"value":"11 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"I certify that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript are the following: Shahrokh Shariat owns or co-owns the following patents: Methods to determine prognosis after therapy for prostate cancer. Granted 2002-09-06. Methods to determine prognosis after therapy for bladder cancer. Granted 2003-06-19. Prognostic methods for patients with prostatic disease. Granted 2004-08-05. Soluble Fas: urinary marker for the detection of bladder transitional cell carcinoma. Granted 2010-07-20. He is an advisory board member of Astellas, Cepheid, Ipsen, Jansen, Lilly, Olympus, Pfizer, Pierre Fabre, Sanofi, Wolff. He is the speaker for Astellas, Ipsen, Jansen, Lilly, Olympus, Pfizer, Pierre Fabre, Sanochemia, Sanofi, Wolff.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted according to the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}